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Merck is implementing a question-based Translational Medicine Guide (TxM Guide) beginning as early as
lead optimization into its stage-gate drug development process. Initial experiences with the TxM Guide,
which is embedded into an integrated development plan tailored to each development program,
demonstrated opportunities to improve target understanding, dose setting (i.e., therapeutic index), and
patient subpopulation selection with more robust and relevant early human-based evidence, and
increased use of biomarkers and simulations. The TxM Guide is also helping improve organizational
learning, costs, and governance. It has also shown the need for stronger external resources for validating
biomarkers, demonstrating clinical utility, tracking natural disease history, and biobanking.Introduction
Merck believes that emphasizing translational medicine
approaches from lead optimization through clinical proof of con-
cept (cPoC), offers opportunities to disruptively improve Phase II
and Phase III clinical success rates. Over the past three years, Merck
has realigned its science, refined its decision processes, and begun
changing program team mindsets to place translational medicine
at the core of its drug development approach.
Despite the increase in the number of new molecular entities
(NMEs) approved by the US Food and Drug Administration in 2014
[1], the most recent evidence from the Tufts Center for Drug
Development indicates that the cost per approved NME continues
to rise [2]. In 2010, a team from Eli Lilly & Co. demonstrated that
Phase II and Phase III clinical trial failure rates were the most
important contributors to the drug development productivity
crisis [3]. Their findings are consistent with the experience of
Merck.Corresponding author:. Trusheim, M. (trusheim@mit.edu)
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Merck is a leading science and technology company in healthcare,
life science, and performance materials, and is headquartered in
Darmstadt, Germany, with its biopharmaceutical business operat-
ing in the USA as EMD Serono. Its development pipeline focuses on
oncology, immuno-oncology, and immunology. As a mid-size
biopharmaceutical firm, the incremental translational medicine
process becomes transformative by delivering more robust cPoC,
such as with its anti-programmed death ligand 1 (PDL1) program
(avelumab) partnered with Pfizer Inc. and recent orphan drug, fast
track, and breakthrough designations granted by the FDA for
metastatic Merkel cell carcinoma.
Public consensus is building on the approaches and rigor re-
quired for successfully translating basic science into clinically
useful therapeutic candidates [4]. Translational medicine advances
in areas such as disease model validation, human cell- or tissue-
derived models, molecular characterization of retrospective hu-
man materials through biobanks, bioinformatics, and translation-
al pharmacokinetics/pharmacodynamics (PK/PD) all suggest
opportunities to learn more preclinically, which should deriskcense (http://creativecommons.org/licenses/by/4.0/).
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FIGURE 1
The three translational medicine aspirations with representative techniques for each. Abbreviations: cPoC: clinical proof of concept; PD, pharmacodynamics; PK,
pharmacokinetics; TxM, translational medicine.
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cine biomarkers into new clinical trial designs, such as adaptive
trials, is providing hope and early evidence that stratified medi-
cine6 will also improve therapeutic success rates.
Moving from exceptional examples of translational medicine
success to systematic improvements in drug development produc-
tivity requires consistent orchestration of translational medicine
thinking and methodology into the routine rhythms of drug
development. Implementing translational medicine requires
changes in scientific management and mindset as well as scientific
technique. Frameworks such as the AstraZeneca 5R framework [5]
and the Pfizer Model Based Drug Development [6,7] similarly
emphasize the integration of scientific and process innovation.
These frameworks provide compelling principles but do not reduce
them to practical tools for use by program teams that are adaptable
to each therapeutic area and that encourage scientifically appro-
priate and financially feasible evidence generation at each devel-
opment stage.
Actionable aspirations: target, dose, and patient
The Merck TxM Guide condenses the process to asking the right
questions to develop the right evidence at the right decision point
timing to achieve three actionable TxM aspirations (Fig. 1):6 ‘Precision medicine’, ‘targeted therapies’, and ‘personalized medicine’ are all
terms used to describe different nuances of employing molecular and other
translational techniques to better match treatments with the patient popula-
tions that will most benefit from them. We use ‘stratified medicine’ consistently
throughout this article as an approximate synonym for all these terms.
518 www.drugdiscoverytoday.com(i) ‘Trust in Target’: identify the right biological target and
understand its role in a particular disease. This aspiration
requires evidence demonstrating that modulating the target
generates clinically relevant physiological effects. In addition,
we aspire to quantify the variability of patient response
(efficacy) to that target modulation, and examine the
commercial approach to exploit that variability by end of cPoC;
(ii) ‘Trust in Therapeutic Window’: identify the right molecule
that delivers the right exposure at the target site of action and
elicits the desired target modulation over the stated time
period (dose, regimen, and molecule), without compromis-
ing patient safety by the end of cPoC. To focus teams on the
critical outcome(s) of this pillar, and for graphical simplicity,
the title of this aspiration is sometimes shortened to ‘dose’ or
‘dose & drug’; and
(iii) ‘Trust in Targeted Patient Population’: define the right
patient population with any needed stratification strategies
and companion diagnostics validated before initiating Phase
III trials.
These three aspirations grew from experiences both with suc-
cessful and disappointing drug development programs. A catalyz-
ing experience for Merck was the success of the epidermal growth
factor receptor (EGFR) and then KRAS biomarkers to select patients
with colorectal cancer who were most likely to respond to cetux-
imab (Erbitux1), which demonstrated the power of the Trust in
Targeted Patient Population aspiration. This postauthorization
KRAS stratification success pointed to the intense translational
science required to make stratified medicine a systematically
prospective development strategy rather than a serendipitous,
life-cycle management exercise.
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oncology experiences involving the increased availability of hu-
man-derived preclinical research resources, such as nonimmorta-
lized cell lines (i.e., explant models), mouse xenograft models,
biobank sample access, improved bioinformatics, translational
informatics, and translational PK/PD capabilities. Evidence of drug
target-associated human cell death and human tumor xenograft
shrinkage combined to provide stronger (or weaker) human trans-
lation preclinical evidence for candidate drugs than that provided
by traditional rodent models. The Nanovacc example (Box 1)
illustrates therapeutic vaccine optimization using human in vivo
T cell approaches.
The Trust in Therapeutic Window aspiration combines efficacy
and safety, which the frameworks referenced above separate.
Efficacy and safety are intimately interconnected through the
candidate drug interactions with intended and unintended tar-
gets. Properties such as its structure, distribution, and disposition
are best assessed simultaneously to understand whether a dosing
regimen that provides significant clinical benefits with acceptable
safety profile is likely to exist.
Negative program experiences resulting from poor translational
medicine understanding of these connected factors motivated this
combination. Dosing uncertainty from inadequately understood
target engagement reduced early clinical trial informativeness,
which in turn contributed to some programs requiring expensive
multiple dose arms in Phase III trials (e.g., cilengitide). This can be
mitigated by using semimechanistic population PK models to
estimate appropriate dose regimens, as demonstrated by the abi-
tuzumab program (Box 2).
Deceptively simple, these TxM aspirations require profound
changes to build the scientific evidence by the stated timing.
For instance, understanding varying target modulation impact
on patient response requires deep disease biology understanding
as well as early clinical trials powered to understand variability, not
simply to test average responses. In general, each aspiration
requires deeper scientific understanding using better, more hu-
manized models or banked human samples and larger, multi-
objective early clinical trials. We believe that achieving these
three results will result in robust cPoCs, improved success rates
in Phase II and Phase III trials, and ultimately higher drug devel-
opment productivity that benefits patients and the healthcare
ecosystem from discovery to payers.
Creating the TxM Guide
The TxM Guide is the centerpiece of the translational medicine
strategy at Merck to connect the three translational aspirations to
practical, creative activity across the drug development stages. It
uses a series of strategic drug development questions from lead
optimization to cPoC to prompt project teams as they create
candidate therapy development plans. The questions balance
immediate actions with long-term thinking and ensure that trans-
lational medicine approaches are leveraged whenever possible.
The TxM Guide also fosters knowledge sharing throughout the
research and development (R&D) value chain. Finally, it enhances
the go/no-go decision-making processes at both project and port-
folio levels.
The TxM Guide began in 2011 with efforts to systematically
encourage translational medicine. Emerging out of biomarker andstratified medicine visions, a broad effort gathered a summary
listing of more than 200 translational medicine questions and
criteria. In mid-2013, Merck R&D leadership commissioned a TxM
Guide creation process to: (i) create a common understanding of
the required available science from the decision to start lead
optimization (DPLO) through cPoC to meet the translational
medicine aspirational goals; (ii) encourage development-stage
appropriate strategies for generating patient-focused, quantitative
translational evidence via a question-based approach; and (iii)
guide project teams and functions to create well-designed quanti-
tative experiments to answer the required phased questions.
The process engaged a cross-functional team from the research
and experimental medicine functions, therapeutic areas, and the
strategy and program management office. The TxM Guide was
delivered to senior management in December 2013, who autho-
rized rollout of the process and training materials company wide
to begin in Q1 2014. Project teams implement the Guide as they
approach their next decision point, resulting in a natural, staged
dissemination.
Although each project is unique, the TxM Guide is designed for
use by all therapeutic areas and nearly all projects, whether small
molecule, biologic, or cellular. It also supports joint development
projects and the inlicensing evaluation of external opportunities.
TxM Guide highlights
An integrated process
The TxM Guide is embedded in the integrated development plan
(IDP), which itself is the primary mechanism for driving program
strategy, planning, and investment governance at Merck. Func-
tional and clinical development plans are subsequently con-
structed in context of the IDP, to conduct the experiments to
answer the identified strategic questions by the required dates and
within the agreed budgets. We believe that it is important that
translational medicine becomes integral to existing development
processes, not separate from them. Although these processes focus
on individual projects, a separate portfolio process draws from the
program IDPs, but is beyond the scope of this paper.
One TxM Guide objective is to encourage long-term thinking
within project teams and the governance process. Therefore, in
addition to answering the questions for the immediate decision
point, teams presenting their product strategy to the decision
bodies include proposed approaches for achieving success at each
of the next two decision points. They articulate the needed experi-
ments and recommend go/no-go decision criteria for each strate-
gic question.
Connecting TxM aspirations to decisions
The TxM Guide links each TxM aspiration to the standard devel-
opment phases by tailoring the strategic questions to each devel-
opment phase and by clearly defining four TxM milestones to
achieve during those phases, with cPoC as the last. Figure 2
illustrates where the four TxM milestones are expected to be
achieved along the classic development stages, but they are not
strictly tied to those positions. This duality allows straightforward
integration of the new translational science milestone concepts
into the existing stage-gate drug development process and gover-
nance. Figure 2 also shows the Merck names for the decision gates
between each classic development stage and, through the arrows,www.drugdiscoverytoday.com 519
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BOX 1
Nanovacc: target pillar
TxM strategic question(s)
DPLO; Dose & Drug: What are the optimization parameters to meet
the candidate drug target profile and how much optimization is
required?
Impact example
Developing a therapeutic cancer vaccine candidate through
optimization of the physical and/or chemical characteristics of its
drug substance and drug product.
Impact
A therapeutic cancer vaccine, Nanovacc, was developed that
introduces a recombinant human survivin protein to the host
immune system. Nanovacc was built upon lessons learned from
earlier tecemotide (formerly Stimuvax) and Survivac vaccine
programs. An integrated and crossfunctional approach was utilized
in the development process.
Background and context
Nanovacc is a therapeutic cancer vaccine candidate that targets
the tumor antigen, survivin. Survivin represents an ideal target for
cancer immunotherapy because it is selectively overexpressed in
most human malignancies and promotes the survival of cancer
cells by inhibiting the intracellular apoptotic machinery. Nanovacc
introduces a recombinant human survivin protein to the host
immune system by encapsulating the protein in a liposomal
nanoparticle containing the cationic lipid DOTAP as a potent
vaccine adjuvant (Fig. B.I). Nanovacc is designed to efficiently
engage the adaptive immune system, leading to the induction of
survivin-specific CD4+ and CD8+ T cell responses and the
development of survivin-specific antibody titers.
Project objectives
(i) Determine the balance of antigen-specific CD4+ and CD8+ T cell
responses desirable for a therapeutic cancer vaccine; (ii) identify
immunological readouts that qualify as relevant surrogates for
anticancer efficacy; and (iii) determine which vaccine properties
need to be assessed and how to generate the required bandwidth
of candidate properties for identification of optimal
pharmacological benefit.
Outcome
A cancer vaccine candidate was developed that has antitumor
activity in a monotherapy setting, and can also be combined with
standard-of-care chemotherapy and novel immune-based
therapies from the Merck Serono portfolio. Nanovacc was
extensively optimized for physical and/or chemical characteristics
that induce a balance of survivin-specific CD4+ and CD8+ T cell
responses in vivo. Importantly, the optimization process balanced
in vivo performance with the requirements of a pharmaceutical
drug product.
Key lessons
The optimization process for Nanovacc required a cyclical
interaction among protein and cell sciences (PCS), chemical and
pharmaceutical development (CPD), and immuno-oncology (iONC),
in which one aspect of the vaccine was altered while attempting to
keep all other physical and/or chemical characteristics constant.
The results of in vivo pharmacology testing by iONC were provided
as feedback to PCS and CPD to inform the next round of
optimization. Through this iterative process, the final physical and/
or chemical characteristics of the Nanovacc vaccine (Table B.I)
were identified as being optimal for both a pharmaceutical
product and a therapeutic cancer vaccine.
Nanovacc benefited from earlier vaccine programs. Where
possible, discovery program teams should study the discovery
and development phases of related molecules to glean lessons
learned from earlier projects. Early input from manufacturing,
clinical, and regulatory colleagues can improve the efficiency of
discovery phase projects.
Novel lipsomal R-DOTAP formulation with
inherent adjuvant activity
Post-translational modification 
(gluconoylation) for enhanced immune
activation
Optimized particle size for
enhanced uptake by APCs 
Nearly full-length survivin protein for 
broad HLA coverage to elicit CD4+
and CD8+ T cell responses
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FIGURE B.I
Nanovacc: a next-generation vaccine. Abbreviations: APC, antigen-
presenting cell; HLA, human leukocyte antigen.
TABLE B.I
Optimization parameters
Parameters Values
R-DOTAP concentration 4 mM
Particle surface charge +18 mV
Vaccine payload 0.5 mg/ml
Particle size 200 nm
Helper lipid composition Phosphatidyl cholines, cholesterol
Excipients of cryopreservation 2.5% sucrose
Survivin protein sequence 2–120 amino acids
Survivin protein modification 40% gluconoylation
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BOX 2
Abituzumab: dose pillar
TxM Guide strategic question(s)
DP2; Dose & Drug: what is the refined, predicted exposure–
response relation using Phase I and available nonclinical data?
Impact example
Establishing the concentration profile saturating the target for a
monoclonal antibody (mAb) without a reliable biomarker or clinical
endpoint.
Impact
A semimechanistic population PK model was developed to guide
dose selection for a mAb for Phase II trials.
Background and context
Abituzumab (EMD 525797, DI17E6) is a deimmunized monoclonal
immunoglobulin (Ig)G2 antibody directed against the alpha-V
subunit of human integrin receptors and is being developed for
the treatment of cancer. It has been demonstrated that members
of the alpha-v-integrin family have a direct role in tumor
progression, tumor angiogenesis, and metastasis. Abituzumab
binds specifically to the alpha-V-chain, thereby inhibiting ligand
binding to all alpha-v heterodimers. Therefore, abituzumab has the
potential to inhibit tumor progression by blocking tumor-induced
angiogenesis, preventing tumor growth by targeting tumor cells
directly, and affecting metastatic tumor cell migration.
During the initial clinical development of abituzumab, no
biomarkers or clinical endpoints were available to guide dose
selection for Phase II. Therefore, dose selection was guided by PK,
under the assumption that the nonlinear component of the
clearance was a surrogate for the binding of the antibody to its
target.
Project objectives
(i) Develop a semimechanistic population PK model for
abituzumab incorporating receptor occupancy that forms the basis
of a model-guided dose rationale; and (ii) predict the likelihood of
different dosing regimens to achieve predefined target occupancy
levels in the study population.
Outcome
The PK of abituzumab in humans is best described by means of a
two-compartment model with a linear and a nonlinear saturable
elimination pathway, the latter using a quasi-equilibrium (QE)
approximation of target-mediated drug disposition (Fig. B.II,
Table B.II). The saturable elimination pathway was assumed to
constitute receptor-mediated uptake (QE assumption) and
subsequent intracellular degradation through binding of
abituzumab to its putative target alpha-V-integrin. Inhibitory
concentrations (IC50, IC80, IC90, IC95, and IC99) for integrin binding in
humans were calculated based on the point estimate for Michaelis-
Menten constant (Km) determined in the population PK analysis.
Monte Carlo-type stochastic simulations with 500 replicates were
then performed with the population PK model for different doses
and dosing regimens. Based on these simulations, the likelihood of
achieving the predefined target occupancy levels during a dosing
interval were determined (Table B.III).
Key lessons
PK modeling and simulation could provide a rational basis for
supporting dose selection of mAb for Phase II studies in the
absence of proximal or distal biomarker. However, it is strongly
recommended that the exposure–response relation be established
with measured biomarkers.
Saturable
elimination
Vmax
Km
Central 
compartment
V1
Peripheral
compartment
V2
Dose (i.v.)
Q
First-order
elimination
CLcatabolic
Drug Discovery Today 
FIGURE B.II
Abituzumab two compartment PK model. Abbreviations: CLcatabolic, catabolic
clearance; i.v., intra-venous; Km, Michaelis–Menten constant; Q,
intercompartmental clearance; V1, central compartment volume; V2,
peripheral compartment volume; Vmax, maximum rate.
TABLE B.II
Population PK model parameter estimates and bootstrap
confidence intervalsa
PK parameters NONMEM Bootstrap
Point
estimate
Between-
subject
variability (%)
Median 90%
Confidence
interval
Vmax, mg/h 493 21.4 498 447–552
Km, mg/ml 0.571 ND 0.561 0.272–0.795
Increase of
Vmax in
patients with
mCRPC (%)
35.3b NA 29.0 –8.5–60.4
V1, L 4.41 22.0 4.43 4.20–4.67
V2, L 3.44 40.4 3.48 2.92–4.05
Q, L/h 0.0444 56.9 0.0436 0.0349–0.0556
CLproteolytic, L/h 0.00857 25.8 0.00861 0.0069–0.0113
a Abbreviations: CLproteolytic, proteolytic clearance; mCRPC, metastatic castrate-resistant
prostate cancer; NA, not applicable; ND, not determined; Q, intercompartmental
clearance; V, volume; Vmax, maximum rate.
b To be re-evaluated in future analysis iterations.
TABLE B.III
Probability of achieving predefined target occupancy in serum
for dosing regimens with a 2-week dosing interval
Dose every
2 weeks, mg
Probability for trough concentration to exceed, %
IC50 IC80 IC90 IC95 IC99
250 41 31 23 12 0
375 91 89 84 77 10
500 99 98 98 97 49
750 100 100 100 100 95
1000 100 100 100 100 100
1500 100 100 100 100 100
Abbreviation: IC, inhibitory concentration.
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FIGURE 2
Overlaying translational medicine milestones onto the stage and/or gate of the drug development process. Proof of principle: demonstrate the beneficial
therapeutic effect on the targeted disease process or pathophysiology (i.e., demonstrate that target modulation and/or activation modifies the desired disease
biology). Proof of concept: demonstrate that modified disease biology translates into a beneficial therapeutic effect on clinical outcomes. Abbreviations: CDTP,
clinical discovery target profile; cPOC, clinical proof of concept; cPOP, clinical proof of principle; DP, decision point; DPED, decision point exploratory development;
DPLO, decision point lead optimization; pPOC, preclinical proof of concept; pPoP, preclinical proof of principle; TPP, target product profile.
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product profile (TPP), which describes the intended claims the
candidate drug must achieve to provide value to patients and the
healthcare system. Before a full TPP, the candidate drug target
profile (CDTP) defines the desired preliminary candidate drug
attributes enabling the future TPP. Given that it is focused on
the path for a single program, Fig. 2 does not illustrate the reverse
translation that occurs from late-stage programs to earlier stage
ones.
The TxM milestones progress from demonstrating target mod-
ulation relevance to fundamental disease biology effects to gross
phenotype impact in disease models to then demonstrating in
humans that target modulation produces disease-relevant bio-
marker changes, and ultimately, human phenotypes of clinical
significance. These TxM milestones emphasize understanding the
translational medicine of efficacy and augment rather than replace
the stage-gate decision point criteria, which are replete with safety,
manufacturing, competition, and other criteria. Although the
emphasis may shift from target to therapeutic window to patient
groups, all three translational aspirations are addressed at each
milestone:
(i) preclinical proof of principle (pPoP): the demonstration of a
beneficial therapeutic effect by a precandidate drug on a
targeted disease process or pathophysiology, showing
modulation or activation of the target in the desired disease
biology. pPoP is mainly assessed using distal PD biomarkers,
such as markers of proliferation or apoptosis for candidate
oncology therapies;
(ii) preclinical proof of concept (pPoC): the demonstration that
disease biology modified by the precandidate drug translates
to a beneficial therapeutic effect on outcomes in disease-
relevant, preclinical models, such as nonimmortalized
human xenograft shrinkage. In some cases, pPoC can be
shown with a well-characterized surrogate molecule;
(iii) clinical proof of principle (cPoP): the demonstration of a
beneficial therapeutic effect of the candidate drug in the
identified patient population on a specific disease process or
pathophysiology. At cPoP, therapeutic effect evaluation is522 www.drugdiscoverytoday.comtypically based on distal PD biomarkers, such as downstream
gene expression or elevations of blood-circulating markers of
metabolic or apoptosis effects. In some cases, clinical scores
that demonstrate gross phenotype changes in inflammation
or mobility may already be available; and
(iv) cPoC: the modification of disease biology by the candidate
drug translating to a beneficial therapeutic effect on clinical
outcome in the identified patient population. cPoC should
be based on clinically significant outcomes or surrogate end
points whenever possible.
The TxM Guide questions
Rather than providing a checklist of required evidence and only a
list of criteria for each decision point, the TxM Guide uses a
question-based approach aligned to key decision points. Others
have demonstrated the advantages of a question-based approach
[8], while the FDA has adopted a question-based review (QbR)
approach for Office of Pharmaceutical Science evaluation of new
drug applications (NDAs) in conjunction with the International
Conference Harmonization (ICH) guidance [9]. Our design fosters
scientific and critical thinking by the teams to ensure the delivery
of the right science at the right time.
The TxM Guide provides teams with a set of strategic drug
development questions (strategic questions) aligned to each de-
cision point from lead optimization through Phase II clinical
development, arranged by themes such as biomarkers and com-
panion diagnostics (Fig. 3) or organized by TxM milestone (not
shown). All the strategic questions for a decision point must be
addressed by the team. Generally, there are fewer than ten, as
shown in Fig. 3a for DPED. The questions were developed to apply
to all programs: small molecule, biologic, or cellular therapy; in
any of our therapeutic areas. Phrased as open-ended queries, they
highlight the core science findings required to move a program
forward. Strategic questions are not a long list of detailed yes/no
questions regarding, for instance, whether every preclinical reg-
ulatory study has been performed. Those detailed requirements
are tracked by other operational management systems. Rather, as
shown in Fig. 3, the DPED ‘Dose & Drug’ column contains only
Drug Discovery Today  Volume 21, Number 3 March 2016 REVIEWS
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FIGURE 3
Translational Medicine (TxM) Guide strategic questions. The questions are always arrayed by the three pillars. (a) They are usually grouped by decision point to
provide an overview of all the TxM issues that need to be addressed to move a program forward. To move forward, a project team must demonstrate evidence for
each question for the decision point plus a plan to generate the required information for the next two decision points. (b) The strategic questions also can be
arrayed by major theme, such as the biomarker and companion diagnostic theme, to facilitate planning for evidence strengthening over time. Abbreviations: CDTP,
clinical discovery target profile; cPOC, clinical proof of concept; cPOP, clinical proof of principle; DP, decision point; DPED, decision point exploratory development;
DPLO, decision point lead optimization; pPOC, preclinical proof of concept; pPoP, preclinical proof of principle; TPP, target product profile.
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precandidate drug been identified with the desired exposure–
response relationship and translatable biomarkers?’ and ‘What
is the expected therapeutic window based on preliminarynonclinical safety data?’. These questions prompt productive
scientific discussions, but do remove the comfortably simplistic
scoring metrics of yes/no checklists, or red/yellow/green
scorecards.www.drugdiscoverytoday.com 523
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tactical drug development questions (tactical questions) serves as a
helpful tool to keep teams focused on detailed translational medi-
cine best practices by asking whether specific approaches, designs,
tools, animal models, simulation techniques, and other factors
could prove effective for this particular candidate.
The question-based approach extends to senior management
program go/no go decision making. Merck leadership desires
evidence-based, scientific discussion of development options fo-
cused on the critical uncertainties rather than a single recommen-
dation for a binary decision. This requires a cultural change as well
as a mindset change among the meeting participants and a
restructuring of meeting agendas to reserve appropriate time.
The three translational medicine aspirations drive the strategic
questions and provide the urgent, transformative power that the
decision process harnesses and directs. For example, the therapeutic
window (dose) goal to understand the therapeutic index by the cPoC
requires strong preclinical modeling to set the Phase I regimen and
superb PD and target engagement biomarkers to assess whether
optimal modulation has occurred. Without such advanced transla-
tional medicine, we cannot understand whether a dose could be
lowered to improve patient safety while maintaining strong efficacy.
Achieving this aspiration requires attention, and investment,
far earlier in the process to develop the biomarkers, establish the
exposure–effect relation models, and understand the translatabili-
ty of animal model evidence to human response projections. For
example, the biomarker strategy (Fig. 3b) prompts identification
and even selection of human translatable PD biomarkers as a
question to be addressed before exploratory development (deci-
sion point DPED). This means human translatable biomarker
science must begin during lead optimization, three development
stages before first-in-human trials.
Successfully achieving the target aspiration proves critical in
assessing whether a disappointing clinical outcome resulted from
inadequate target engagement or because the target itself does not
have the disease intervention power for which we hoped and
planned. Historically, these uncertainties could cause us to pursue
high-risk Phase III trials with multiple dosing arms; launch pro-
ducts with nonoptimal dosing regimens; or even cancel programs
due to inadequate formulations and inadequate time to create
them.
The patient aspiration to define the stratified patient population
complete with a validated companion diagnostic (where relevant)
before entering Phase III requires that Phase II trials no longer act
as exploratory human functional genomics experiments searching
to discover both treatment response variability and a biomarker to
distinguish that variability. Rather, the TxM Guide prompts the
search for clinically relevant pathway and target variability back at
the decision point to enter lead optimization, even when the
therapeutic concept itself does not target a genetic mutation.
Without the clearly stated goal to define the target patient popu-
lation and, in relevant cases, validate the companion diagnostic
before Phase III trials, the impetus to explore and invest in human
preclinical evidence would be significantly lower.
Early experiences
While it is too early to statistically evaluate the TxM Guide (em-
bedded into the IDP) impact on the Merck pipeline, some early524 www.drugdiscoverytoday.comscientific and management findings exist. Regarding R&D man-
agement process, the project teams reported that the TxM Guide
question-based process helped identify evidence gaps and coordi-
nation issues, and prompted more systematic external environ-
ment scanning. For instance, 80% of the program leaders reported
that the IDP was helpful and actively used by the team to translate
the strategy into activities, as well as helping justify the resource
needed to perform those activities. Importantly, they also noted
that the TxM Guide forced true crossfunctional scientific planning
and design rather than parallel function thinking.
As with most corporate cultural and mindset changes, senior
leadership commitment to advocate and implement the changes
has proven critical. Actions proving pivotal ranged from the
integration of translational medicine into strategic company-wide
communications as well as simplifying organizational structures at
a high level, to the practical structure of project review sessions to
focus discussions on strategic questions. Investing the resources to
perform the early TxM science while simultaneously advancing
late-stage trials that have not had the benefits of such science
remains a scientific and financial tension not fully resolved. How-
ever, what is clear is that project teams hold scientifically richer
program strategy discussions and that the IDP/TxM Guide is rescu-
ing senior leadership from detailed checklist reviews and restoring
focus on scientific discussions for the most critical program deci-
sions.
The TxM Guide has supported, gathered, and promoted best
practices from around the company. In one example, a project
team in exploratory development determined the PD efficacy
relation using preclinical human-based evidence, which effective-
ly provided the rationale for selecting the starting dose. Specifical-
ly, the Phase I clinical trial dosing design used human tumor
mouse xenografts to estimate the extent and duration of target
engagement required to generate meaningful tumor growth inhi-
bition.
In another example (Box 2), the abituzumab oncology project
team established the concentration profile for the monoclonal
antibody required to saturate the target, without a reliable target
modulation biomarker, through the use of a semimechanistic
population PK model. Based on a PK simulation using a two-
compartment model, the likelihood of achieving the predefined
target occupancy levels during a dosing interval could be deter-
mined. Two doses for a Phase II study were then selected that
achieved different levels of target saturation in the study. While
biomarker evidence is highly preferred, the abituzumab experi-
ence demonstrated that PK modeling and simulation may provide
a rational basis for supporting dose selection [10].
A reverse translational medicine example occurred within the
Nanovacc cancer vaccine development program (Box 1). The
optimization process for Nanovacc required a cyclical interaction
among departments by which the program benefited from earlier
vaccine encapsulation study experience and biological activity
assay results. This back-translation accelerated the process as well
as set optimization stopping criteria. Nanovacc provides a tangible
example of how the manufacturing, clinical, and regulatory expe-
rience gained from related prior programs improves the efficiency
of a discovery phase project.
Finally, as described in Box 3 with a follicle-stimulating hor-
mone receptor (FSHR) project, creative use of human cell models
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BOX 3
FSHR agonist
TxM strategic question(s)
DPLO; Dose & Drug: what are the optimization parameters to meet
the candidate drug target profile and how much optimization is
required? Does at least one lead series and/or antibody have the
potential to deliver the essential attributes of the candidate drug
target profile?
Impact example
Translational PK/PD modeling based on a human exposure–
potency relation and rat in vivo PK/PD (oocytes count) to estimate
the human dose range for an oral, small-molecule preclinical FSHR
agonist, MSCx, using a marketed large molecule, recombinant FSH
(human follitropin alfa; Gonal-fW, administered subcutaneously).
Impact
By establishing a PK/PD relation using Gonal-f, and validating this
relation for an oral, small molecule, MSCx, optimization parameters
were determined to meet suitable human dose levels for this hit
series.
Background and context
FSHR is a G-protein-coupled receptor that binds FSH, a hormone
essential for human fertility. FSHR is a highly validated target. It
upregulates serum estradiol, a well-established biomarker for
activation of FSHR. Merck Serono markets Gonal-f (follitropin alfa
for injection), which is a large molecule that stimulates follicle
development and maturation, and is used clinically for ovulation
induction and assisted reproductive technologies. An oral FSHR
agonist, MSCx, was developed by EMD Serono.
Project objectives
(i) Develop a PK/PD relation for MSCx based on the ratio of human
exposure to Gonal-f at the therapeutic dose (150 IU at steady state)
versus in vitro EC50 for estradiol release measured in human
granulosa cells to understand the target activation needed for
efficacy. The PK/PD relation was confirmed by a rat PD model using
oocytes count as a marker; (ii) determine the distance of the
current lead compound relative to the target maximum human
dose of 100 mg four times daily, which was set up arbitrarily by the
therapeutic area research unit to minimize any safety concern; and
(iii) select the key parameters for optimization based on the
distance to human dose and properties of the lead compound.
Outcome
A PK/PD relation was established for MSCx, and the optimization
parameters target potency, log P value, and in vivo clearance to
reach an effective dose in humans were determined. As a result,
the hit series was declared as a lead series, because the work
demonstrated that the lead series could be optimized during the
lead optimization phase by improving potency, decreasing log P
value, and decreasing in vivo clearance.
Key lessons
The duration and effect of the lead compound on the target was
unknown during the hit optimization (HO) phase of the project;
therefore, it was unknown how much optimization and what kind
of CDTP was needed to reach a suitable human dose level. By
establishing a PK/PD relation using human PK and in vitro potency
profile for Gonal-f (Table B.IV) and validating this relation for MSCx
in rats using oocytes count as a biomarker (Figs. B.III and B.IV), the
optimization parameters needed to reach an effective dose in
humans were determined. It was found that a 100-fold increase in
the exposure–potency relation was needed to achieve the desired
human dose range. Based on the current structure–activity relation
of the compound library, this was a realistic goal.
TABLE B.IV
FSH.
Compound Free EC50
(ng/ml)
Target concentration
range (ng/ml) (free Css)
for comparable efficacy
to FSH
Free EC50:free
Css ratio
Human FSH
(Gonal-fW)
17.75
(in human)
0.37–0.67 in human
(observed, 150 IU SC)
48–26
MSCx 731
(in human)
15–28 in human
(predicted)
48–26 (based
on FSH ratio)
1193 (in rat) 25–45 in rat (predicted) 48–26 (based
on FSH ratio)
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FIGURE B.III
Rat plasma concentration.
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FIGURE B.IV
Rat oocyte count as an efficacy biomarker. At 100 mg/kg twice daily (bid),
efficacy observed for MSCx was comparable to the maximal efficacy induced
by follicle-stimulating hormone (FSH) (arrow). Exposure above Css, min for at
least 12 hours daily seems to be needed for comparable efficacy to FSH.
Abbreviation: Css, plasma concentration at steady state.
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lead series could be optimized. The duration and effect of a lead
compound on the target was unknown; therefore, the required
candidate drug target profile parameters to reach a suitable human
dose level could not be defined. By establishing a PK/PD relation
using human PK and in vitro potency profile for Gonal-f and
validating this relation for the lead compound in rats using
oocytes count as a biomarker, it was found that a 100-fold increase
in the exposure–potency relation was needed. Based on the current
structure–activity relation of the compound library, this assess-
ment concluded that achieving the potency goal was likely.
Future directions and concerns
As Merck continues to roll out the TxM Guide as project teams
approach their next eligible decision points, we are addressing
cultural, operational, and capability gaps. Translational medicine
requires a mindset change, as noted by academia and industry alike
[4,11]. We continue to evolve our training materials, expert team
advisors, external partners, incentives, and feedback mechanisms.
As we use the TxM Guide, we are working to develop better ways to
visualize the achievements across multiple questions. Perhaps most
importantly, we continue to evaluate the lessons learned from both
successes and failures, and use those learnings to ‘back-translate’
into our TxM Guide and ongoing program IDPs.
Operationally, our experiences are highlighting the need for
internal standards (when external standards do not exist) for the
biomarker data from discovery through submission to enable data
pooling across projects, which is essential to reverse translation.
Doing so without stifling scientific creativity and adaptability to
the specific needs of each program proves challenging.
The TxM Guide process has highlighted scientific capability
gaps. Some areas, such as translational PK/PD biomarkers, are best
addressed internally in the context of each candidate drug. How-
ever, many gaps also exist in community resources, particularly
those regarding populations, disease attributes and natural526 www.drugdiscoverytoday.comhistory, validation of models to recapitulate human phenotypes,
and platforms to rapidly develop models, simulations, biomarkers,
and diagnostics.
We commend the disease foundation community for advancing
many of these resources. Industry also has a role in supporting these
efforts and in multiparty precompetitive consortia. We also encour-
age public funders to support long-term resources as well as project-
based research. Too often, public resources from bioinformatics
repositories to biobanks struggle to find reliable public funding
support to the detriment of the entire community. We also strongly
support strengthening data standards and methods transparency in
scientific publications to enable results replication.
Answering the questions raised by the TxM Guide will require
continued change in our mindset, with the tools we use, to the
processes we employ and, increasingly, with the number, depth,
and quality of the collaborations and consortia in which we
participate as we strive to deliver more therapies rapidly, safely,
and effectively to patients globally.
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